UBS Group set a €96.00 ($111.63) target price on Merck KGaA (FRA:MRK) in a report published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other research firms have also commented on MRK. HSBC set a €96.00 ($111.63) price target on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 15th. Bank of America set a €110.00 ($127.91) target price on Merck KGaA and gave the company a neutral rating in a research report on Friday, September 13th. DZ Bank reaffirmed a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the company a buy rating in a research report on Friday, September 6th. Finally, Barclays set a €85.00 ($98.84) target price on Merck KGaA and gave the company a sell rating in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company. Merck KGaA currently has an average rating of Hold and an average target price of €101.88 ($118.47).
Shares of MRK traded up €1.85 ($2.15) during trading hours on Thursday, hitting €108.00 ($125.58). The company had a trading volume of 770,765 shares. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72). The company’s fifty day moving average price is €105.44 and its two-hundred day moving average price is €96.92.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: What is meant by holder of record?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.